Haemonetics (NYSE:HAE) Issues FY 2027 Earnings Guidance

Haemonetics (NYSE:HAE) issued an update on its FY 2027 earnings guidance on Thursday morning. The company provided EPS guidance of 5.258-5.307 for the period, compared to the consensus EPS estimate of 5.290. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Haemonetics Stock Down 5.6%

HAE stock opened at $52.52 on Thursday. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15. The company’s 50 day simple moving average is $59.68 and its 200-day simple moving average is $66.65. Haemonetics has a 12 month low of $47.31 and a 12 month high of $87.32. The firm has a market capitalization of $2.44 billion, a PE ratio of 14.47, a P/E/G ratio of 1.09 and a beta of 0.53.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.01. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Equities analysts expect that Haemonetics will post 4.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on HAE shares. Citigroup cut their price target on Haemonetics from $75.00 to $70.00 and set a “neutral” rating for the company in a report on Wednesday, March 11th. Mizuho decreased their price objective on Haemonetics from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. BTIG Research reissued a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a research note on Friday, February 6th. Robert W. Baird set a $81.00 target price on shares of Haemonetics in a report on Friday, February 6th. Finally, Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $82.78.

Hedge Funds Weigh In On Haemonetics

Institutional investors have recently added to or reduced their stakes in the business. Quantinno Capital Management LP lifted its position in Haemonetics by 9.0% during the second quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock worth $261,000 after buying an additional 289 shares during the period. UMB Bank n.a. increased its stake in shares of Haemonetics by 110.9% during the 4th quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 306 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new position in shares of Haemonetics during the 4th quarter worth about $26,000. Empowered Funds LLC boosted its position in shares of Haemonetics by 9.1% in the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after acquiring an additional 372 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.